Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies

NCT01065025 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced and Incurable Solid Tumors
Malignant Lymphomas

Interventions

DRUG: 4SC-205

Sponsor

4SC AG